CTOs on the Move

Biomatrix

www.biomatrix.com

 
Biomatrix, Inc., together with its subsidiaries in Canada, Europe and Asia, develops, manufactures, markets and sells a series of proprietary viscoelastic products called hylans that are used in therapeutic medical applications and skin care. Hylans are
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Kernel Co

Kernel is a human intelligence (HI) company. We`re a team of scientists and engineers on a mission to dramatically increase our quality of life and create a thriving humanity. We believe that starts with a renewed focus on human intelligence (HI). Machines of all kinds can help us along the way, but our vision is one in which we humans maintain and expand our authorial power. The advanced intelligence of tomorrow is a collaboration between the natural and the artificial. United, unheard of possibilities abound. We`re building off two decades of breakthrough research, working closely with private partners and scientists to get usable solutions in the hands of people everywhere. We’re starting with potential applications for patients with cognitive disorders.

Owens Healthcare

Owens Healthcare is a Redding, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Harmac Medical Products

Harmac Medical Products, Inc is a Buffalo, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tearlab

TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.

Osypka Medical

Osypka Medical, Inc. is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.